The efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in Alzheimer's disease.

[1]  M. Roghani,et al.  Riluzole ameliorates learning and memory deficits in Aβ25-35-induced rat model of Alzheimer's disease and is independent of cholinoceptor activation. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  C. B. Mishra,et al.  Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease. , 2017, European journal of medicinal chemistry.

[3]  M. Roghani,et al.  Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer's disease by inhibition of glial activation, cholinesterase, and oxidative stress. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  M. Fernandez-Mestre,et al.  Role of genes GSTM1, GSTT1, and MnSOD in the development of late-onset Alzheimer disease and their relationship with APOE*4. , 2016, Neurologia.

[5]  Young Joon Lee,et al.  Neuroprotective effects of Danggui-Jakyak-San on rat stroke model through antioxidant/antiapoptotic pathway. , 2016, Journal of ethnopharmacology.

[6]  M. Waksmundzka-hajnos,et al.  The influence of common free radicals and antioxidants on development of Alzheimer's Disease. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  C. Ye,et al.  Donepezil attenuates Aβ-associated mitochondrial dysfunction and reduces mitochondrial Aβ accumulation in vivo and in vitro , 2015, Neuropharmacology.

[8]  H. Uzun,et al.  Ischemia‐modified albumin and advanced oxidation protein products as potential biomarkers of protein oxidation in Alzheimer's disease , 2015, Geriatrics & gerontology international.

[9]  K. Nishimaki,et al.  Oxidative stress accelerates amyloid deposition and memory impairment in a double-transgenic mouse model of Alzheimer's disease , 2015, Neuroscience Letters.

[10]  T. Beach,et al.  Role of Environmental Contaminants in the Etiology of Alzheimer's Disease: A Review , 2015, Current Alzheimer research.

[11]  D. Praticò,et al.  The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer’s disease phenotype , 2015, Front. Cell. Neurosci..

[12]  Mohammad A Kamal,et al.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. , 2014, CNS & neurological disorders drug targets.

[13]  Cheng-Hsien Lu,et al.  The Roles of Biomarkers of Oxidative Stress and Antioxidant in Alzheimer's Disease: A Systematic Review , 2014, BioMed research international.

[14]  I. Sadowska-Bartosz,et al.  Oxidative Modification of Proteins in Pediatric Cystic Fibrosis with Bacterial Infections , 2014, Oxidative medicine and cellular longevity.

[15]  Jianting Chen,et al.  Advanced oxidation protein products accelerate bone deterioration in aged rats , 2014, Experimental Gerontology.

[16]  A. Cedazo-Mínguez,et al.  Oxidative Stress in Alzheimer's Disease: Why Did Antioxidant Therapy Fail? , 2014, Oxidative medicine and cellular longevity.

[17]  M. Can,et al.  Ischemia Modified Albumin and Plasma Oxidative Stress Markers in Alzheimer's Disease , 2013, European Neurology.

[18]  R. Omdal,et al.  Improved detection of advanced oxidation protein products in plasma. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[19]  K. Blennow,et al.  Changes in CSF acetyl‐ and butyrylcholinesterase activity after long‐term treatment with AChE inhibitors in Alzheimer’s disease , 2011, Acta neurologica Scandinavica.

[20]  Y. Orhan,et al.  The Serum Protein and Lipid Oxidation Marker Levels in Alzheimers Disease and Effects of Cholinesterase Inhibitors and Antipsychotic Drugs Therapy , 2010 .

[21]  S. Rizvi,et al.  Age-dependent decline in erythrocyte acetylcholinesterase activity: correlation with oxidative stress. , 2009, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[22]  Mukut Sharma,et al.  Chronic Oxidative Stress as a Mechanism for Radiation Nephropathy , 2009, Radiation research.

[23]  H. Uzun,et al.  Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population , 2008, Clinical and Experimental Medicine.

[24]  M. Ghayour-Mobarhan,et al.  Prooxidant-antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. , 2008, Clinical biochemistry.

[25]  F. Saura-calixto,et al.  Study of plasma antioxidant status in Alzheimer's disease , 2005, European journal of neurology.

[26]  M A Lovell,et al.  Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease , 2005, Journal of neurochemistry.

[27]  Rui Wang,et al.  Tacrine attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. , 2002, Brain research. Molecular brain research.

[28]  A. Nordberg,et al.  Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months , 2002, Neurology.

[29]  C. Lauderback,et al.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress , 2002 .

[30]  L. Parnetti,et al.  Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina , 2001, Mechanisms of Ageing and Development.

[31]  L. T. McGrath,et al.  Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. , 2001, QJM : monthly journal of the Association of Physicians.

[32]  Kaj Blennow,et al.  Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease , 2001, Neuroscience Letters.

[33]  H. Zhang,et al.  Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells , 2000, Neuroscience Letters.

[34]  W. Markesbery,et al.  Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF , 1999, Journal of neurochemistry.

[35]  W. Markesbery,et al.  Oxidative Alterations in Alzheimer's Disease , 1999, Brain pathology.

[36]  M. Mattson,et al.  A Role for 4‐Hydroxynonenal, an Aldehydic Product of Lipid Peroxidation, in Disruption of Ion Homeostasis and Neuronal Death Induced by Amyloid β‐Peptide , 1997, Journal of neurochemistry.

[37]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[38]  K. Urakami,et al.  Plasma and Serum G4 Isoenzyme of Acetylcholinesterase in Patients with Alzheimer-Type Dementia and Vascular Dementia , 1990, Annals of clinical biochemistry.

[39]  E. Perry,et al.  Blood acetyl- and butyrylcholinesterases in senile dementia of Alzheimer type , 1985, Journal of the Neurological Sciences.

[40]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[41]  J. Atack,et al.  PLASMA AND ERYTHROCYTE ACETYLCHOLINESTERASE IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1982, The Lancet.

[42]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[43]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.

[44]  D. Gill,et al.  A MICRO-BIURET METHOD FOR ESTIMATING PROTEINS. , 1964, Analytical biochemistry.

[45]  R. Écochard,et al.  Influence of oxidative stress biomarkers on cognitive decline. , 2015, Journal of Alzheimer's disease : JAD.

[46]  Hong Zhang,et al.  Oxidative stress, mitochondrial dysfunction and the mitochondria theory of aging. , 2014, Interdisciplinary topics in gerontology.

[47]  P. Thokala,et al.  Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. , 2013, Age and ageing.

[48]  W. Jagust,et al.  Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load. , 2013, Current Alzheimer research.

[49]  A. Petróczi,et al.  Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors. , 2012, Journal of Alzheimer's disease : JAD.

[50]  U. Çakatay.  Protein Redox-Regulation Mechanisms in Aging , 2010 .

[51]  C. Giulivi,et al.  Current analytical methods for the detection of dityrosine, a biomarker of oxidative stress, in biological samples. , 2007, Mass spectrometry reviews.

[52]  H. Soininen,et al.  Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease , 2005, Journal of Neural Transmission.

[53]  P. Francis,et al.  Cholinesterase Inhibitors Used in the Treatment of Alzheimer’s Disease , 2004, Drugs & aging.

[54]  J. Strain,et al.  Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. , 1999, Methods in enzymology.

[55]  L. Packer,et al.  Oxidative damage to proteins: spectrophotometric method for carbonyl assay. , 1994, Methods in enzymology.

[56]  J. Sedlák,et al.  Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. , 1968, Analytical biochemistry.

[57]  V. Vasić,et al.  Send Orders of Reprints at Reprints@benthamscience.net Acetylcholinesterase Inhibitors: Pharmacology and Toxicology , 2022 .